NCT06400368View on ClinicalTrials.gov

Effect of LEQEMBI on Cerebral and Retinal Amyloid in Mild Cognitive Impairment Due to Alzheimer's Disease

RecruitingOBSERVATIONAL
Enrollment

200

Participants

Timeline

Start Date

April 24, 2024

Primary Completion Date

April 30, 2026

Study Completion Date

April 30, 2026

Conditions
Mild Cognitive ImpairmentAlzheimer Disease
Trial Locations (1)

95816

RECRUITING

Sutter Health, Sacramento

Sponsors
All Listed Sponsors
lead

NeuroVision Imaging

INDUSTRY

NCT06400368 - Effect of LEQEMBI on Cerebral and Retinal Amyloid in Mild Cognitive Impairment Due to Alzheimer's Disease | Biotech Hunter | Biotech Hunter